Bausch Health Companies Inc. (BHC,BHC.TO) on Wednesday reported a first-quarter net loss of $1.423 billion or $3.82 per share, compared with net loss of $58 million or $0.16 per share for the first quarter of 2025.
Adjusted net income for the quarter was $296 million or $0.78 per share, compared to $220 million or $0.59 per share last year.
Total consolidated reported revenues were $2.52 billion for the first quarter of 2026, compared with $2.26 billion in the first quarter of 2025, an increase of $265 million, or 12%. Revenue increased 7% on an organic basis compared with the first quarter of 2025.
"Our first quarter performance marks twelve consecutive periods of year-over-year growth in revenue, adjusted EBITDA for Bausch Health excluding Bausch + Lomb, reflecting strategic execution and disciplined accountability across our organization. We continue to invest in our pipeline, including the advancement of larsucosterol to treat alcohol-associated hepatitis, while pursuing business development opportunities aligned with our strategic priorities. With this momentum, we reaffirm our full-year 2026 outlook and remain focused on driving sustainable performance and shareholder value," said Thomas J. Appio, Chief Executive Officer, Bausch Health.
Looking forward, the company expects full-year revenues of $10.670 billion - $10.920 billion.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.